AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01824381
Drug: amniotic membrane
RxNorm normalized name: Amniotic Membrane Human Ophthalmic Sheet
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02856555
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to firsocostat orally once daily.
Trial: NCT00005603
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00005603
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00005603
Drug: mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00005603
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00573261
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will take placebo for the duration of four weeks. The dosage will range from 75 mg twice a day to 300 mg twice a day.
Trial: NCT02872428
Drug: Isotonic saline solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: By infusion over 1 hour
Trial: NCT00649194
Drug: Aciphex® Tablets 20 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20mg, single dose fed
Trial: NCT03189017
Drug: ICP-022
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The drug product is a white, round, uncoated tablet.
Trial: NCT03189017
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo is a white, round, uncoated tablet.
Trial: NCT00290641
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00840853
Drug: Benadryl and Tylenol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients may be premedicated with Benadryl and Tylenol before receiving the injection of cells.
Trial: NCT03598270
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volume equivalent to 1200 mg of atezolizumab drug product. Intravenous Day 1
Trial: NCT03598270
Drug: Pegylated liposomal doxorubicin (PLD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/m². Intravenous. Day 1
Trial: NCT03106818
Drug: bupivacain with magnesium sulphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: will receive bupivacain 0.125% and magnesium sulphate 5% infusion in the presternum , for 48 hours
Trial: NCT03282318
Drug: ASP6294
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 320 mg ASP6294 subcutaneous injection at 4-week intervals at baseline (Day 1/Week 0), Week 4 and Week 8.
Trial: NCT03282318
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo to match 320 mg ASP6294 subcutaneous injection at 4-week intervals at baseline (Day 1/Week 0), Week 4 and Week 8.
Trial: NCT01302847
Drug: DTG film-coated tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTG film-coated tablets initial starting dose at \~1 mg/kg with a maximum dose of 50 mg; orally once daily. Participants weighing ≥ 35kg received the proposed dose of 50 mg of DTG film-coated tablets.
Trial: NCT01302847
Drug: DTG granules for suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTG granules for suspension initial starting dose at \~0.64 mg/kg with a maximum dose of 32 mg; orally once daily.
Trial: NCT03717896
Drug: 200mg IV thiamine in 50mL 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiamine 200mg IV every 12 hours for 2 days
Trial: NCT03717896
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50mL 0.9% saline
Trial: NCT03860857
Drug: Tau PET scan using MK-6240
RxNorm normalized name: Pet-ema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tau Positron Emission Tomography scan using radio tracer MK-6240
Trial: NCT00233558
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01366131
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous repeating dose
Trial: NCT00003131
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02983747
Drug: Medication Treatment(Loxoprofen Sodium tablets,M)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loxoprofen Sodium tablets(LOXONNIN®, DAICHI SANKYO PHARMACEUTIAL (SHANGHAI) Co . Ltd .)，P.O., 60mg, three times a day
Trial: NCT00387777
Drug: Patch with centrally acting analgesic
RxNorm normalized name: Rauwolfia alkaloids, centrally acting antiadrenergic
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01403051
Drug: EFV/FTC/TDF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla) 600 mg/200 mg/ 300 mg tablet taken orally once daily at bedtime on an empty stomach.
Trial: NCT01403051
Drug: Placebo for calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A placebo for calcium carbonate twice daily taken orally as one x 0 mg tablets with food for 48 weeks
Trial: NCT01769456
Drug: Emtricitabine/tenofovir (FTC/TDF (Truvada®))
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects will be provided with daily FTC/TDF (Truvada®) as Pre-exposure prophylaxis (PrEP) for 48 weeks.
Trial: NCT00966472
Drug: Erlotinib + Rosuvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive Erlotinib 150mg po daily. They will also receive Rosuvastatin at escalating dose levels starting at 1mg/kg po daily for 3 weeks, followed by a 1-week rest period. Patients may continue to receive rosuvastatin and erlotinib in the absence of disease progression or unacceptable toxicity.
Trial: NCT04641104
Drug: Thiamine 500 MG
RxNorm normalized name: thiamine 500 MG
DrugBank: Thiamine (DB00152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A solution of 500 mg of Thiamine Hydrocloride in a solution of 100 ml of NaCl 0.9% will be administered post-cardiac surgery in patients with lactate levels ≥ 2 mmol / L in the first 6 hours post-ICU admission.
Trial: NCT04641104
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 ml of NaCl 0.9% will be administered in the placebo group.
Trial: NCT00042601
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo injection will be supplied in 5-mL multidose glass vials with a rubber stopper
Trial: NCT03280030
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, two capsules, were administered twice per day by mouth on day 8-21 during induction and consolidation phase; then on days 1-28 for 12 cycles in the continuation (post consolidation) phase.
Trial: NCT01109446
Drug: Triamcinolonacetonid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triamcinolonacetonid 40mg/ml. 40mg of Triamcinolonacetonid is mixed with 2ml of Lidocaine 10mg/ml. It is injected deep into the tendon, guided by ultrasound.
Trial: NCT00613808
Drug: Nitric Oxide 200ppm Group B
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 ppm, 8hrs / day for 6 weeks
Trial: NCT00678210
Drug: CP-690,550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablets, 2 mg BID for 12 weeks
Trial: NCT00678210
Drug: CP-690,550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablets, 5 mg BID for 12 weeks
Trial: NCT00678210
Drug: CP-690,550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablets, 15 mg BID for 12 weeks
Trial: NCT00678210
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablets, BID for 12 weeks
Trial: NCT00615199
Drug: CP-690,550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administration via oral route twice daily
Trial: NCT00615199
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administration via oral route twice daily
Trial: NCT03564158
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01216735
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 3 weeks
Trial: NCT02077140
Drug: MDT-10013
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02077140
Drug: Standard of care for pain
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01025414
Drug: enteral nutrition
RxNorm normalized name: ENTERAL NUTRITION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A - enteral feeding was started 2 to 4 hours after catheter placement via enteral tube inserted via endoscope below the Treitz's ligament into first intestinal loop (location of the tip) (Nutricial Ltd. Flocare). The initial flow rate was 10 ml/ hour, final 125 ml/ hour. Energy requirements was calculated using following rule: 0.15-0.2 gN/ kg and 130-170 kcal/ gN. Diet: Peptisorb (Nutricia Ltd.) - oligopeptide diet well tolerated by intestines
Trial: NCT01025414
Drug: Parenteral nutrition
RxNorm normalized name: parenteral nutrition solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral nutrition was started 2 to 4 hours after venous catheter placement (standard Arrow type, the tip located 5 cm over right vestibule, the location confirmed on chest X-ray) and continued until oral diet covering at least 60% of daily caloric and protein demand. The energy requirements were calculated using following rule: 0.15-0.2 gN/ kg and 130-170 kcal/ gN. Parenteral diets: Aminoplasmal 10%, Lipofundin LCT/MCT 10 and 20%, 40% Glucose, Tracutil (microelements and trace elements), Cernevit (vitamins), electrolytes
Trial: NCT01802021
Drug: Astagalus-based Formula: Qingshu-Yiqi-Tang
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plus astragalus-based formula: Qingshu-Yiqi-Tang 7.2gm BID during 1st line chemotherapy and 2nd line target therapy.~maximal for 6 months
Trial: NCT02567279
Drug: Placebo subcutaneous injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of Placebo, one injection at baseline and another injection at 6 months
Trial: NCT02532309
Drug: Rosuvastatin (5mg，10mg，20mg)
RxNorm normalized name: ezetimibe 10 MG / rosuvastatin 20 MG [Roszet]
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin dose adjusted by LDL-c level( If LDL-C\>1.1mmol/L and \<1.8mmol/L, administrated as 5mg/day.If LDL-C ≥1.8mmol/L, adjusted every 4 weeks as 5mg，10mg，20mg.
Trial: NCT02532309
Drug: Rosuvastatin 5mg
RxNorm normalized name: ROSUVASTATIN 5MG CAP,SPRINKLE
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin 5mg/day
Trial: NCT06768632
Drug: Group 1: single-dose of test formulation+single-dose of reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eltrombopag Tablets is a small molecule non peptide thrombopoietin receptor agonist.
Trial: NCT02497911
Drug: Ropivicaine
RxNorm normalized name: Ropivicaine-Sufentanil Citrate
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06770894
Drug: Placebo Tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets 1 a day, provided in identical blisters.
Trial: NCT02574065
Drug: L. reuteri DSM 17938
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Effects on crying time in colicky infants with the supplementation of Lactobacillus reuteri DSM 17938
Trial: NCT04292444
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo nasal sprays contain identical ingredients except for the peptide itself (30 minutes before the start of the tasks).
Trial: NCT01087008
Drug: zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid 4 mg every 4 weeks for a total of 12 treatments
Trial: NCT02696148
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For subcutaneous (s.c., under the skin) injection once daily.
Trial: NCT03317600
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention is a placebo nerve block with isotonic saline
Trial: NCT00781976
Drug: AZD7295
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 700mg per day maximum
Trial: NCT00781976
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matched placebo
Trial: NCT03292250
Drug: BYL719
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be instructed to take BYL719 orally at a dose of 100 mg with a glass of water once daily, in a fasting state or with a light fat-free meal, and as close as possible to the same time each day.
Trial: NCT02045901
Drug: Placebo (Sugar Pill)
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On Day 1, all participants will take 2 tablets of Placebo at bedtime. On Days 2 to 14, participants will take 2 tablets of Placebo at bedtime. The minimum dosage will be 2 tablets daily at bedtime, increasing, when indicated, to the maximal dosage of 4 tablets per day on Days 3 to 14.
Trial: NCT00128401
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01375946
Drug: AG200-15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: There will be three treatment periods. Subjects will be randomly assigned to one of the five conditions for the treatment period. The subject will be exposed daily to the condition assigned while wearing the patch. The study patch will be worn for a 7 day treatment period, followed by a 7 day washout period. The total duration of the study is 6 weeks.
Trial: NCT00015886
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 350 milligrams intraveneously
Trial: NCT05237323
Drug: mycophenolate mofetil 2 g per day
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: mycophenolate mofetil 2 g per day and methylprednisolone in an average starting dose 24 \[24; 32\] mg per day and standard drug therapy for heart failure.
Trial: NCT01587534
Drug: Norzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be randomized to receive either pancreatic enzyme replacement therapy or placebo. Patients will use two capsules three times daily during main meals and one capsule three times daily during in between snacks. The pancreatic enzyme preparation under investigation is Norzyme ® 6 - 9 tablets per day.
Trial: NCT00003334
Drug: pegylated liposomal doxorubicin hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01001052
Drug: Colcrys™ (colchicine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 mg taken by mouth on day 1
Trial: NCT01764737
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose intravenous administration
Trial: NCT02370238
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo oral tablets 1200 mg t.i.d. continuing from D 1 to Day 21 of 28-day cycle
Trial: NCT02134990
Drug: Oshadi D and Oshadi R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti cancer agents
Trial: NCT02819284
Drug: KPI-121 0.25% Ophthalmic Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02819284
Drug: Vehicle of KPI-121 0.25% Ophthalmic Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00943748
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A standard dose-escalation phase will first be initiated, with a 3 ml of the placebo oral solution twice a day (breakfast and dinner) increase every 3 days up to a total of a fixed dose of 9 ml of placebo oral solution twice a day corresponding to 30 mg/kg/day in 2 doses
Trial: NCT01656057
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen dissolved in 50 ml of water
Trial: NCT00000543
Drug: calcium
RxNorm normalized name: Calcium
DrugBank: Calcium sulfate (DB15533)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03936933
Drug: ZOLADEX® 3.6mg Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.6 mg, Subcutaneously at every 28 days
Trial: NCT03517501
Drug: ART-123
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose: 0.06 mg/kg/day up to a maximum dose of 6 mg/day for 6 days
Trial: NCT03517501
Drug: Placebo Comparator - Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose: 0.06 mg/kg/day up to a maximum dose of 6 mg/day for 6 days
Trial: NCT06773429
Drug: E2 Valerate
RxNorm normalized name: valerate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To experimentally elevate E2 levels females received 6mg of E2 valerate (Progynova21©) on two consecutive days (in total 12mg).
Trial: NCT06773429
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pills (blue-colored hard gelatine capsules filled with a mixture of 99.5% mannitol and 0.5% Aerosil (fumed silica)) have been administered for the placebo-controlled condition.
Trial: NCT04575610
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets will be administered.
Trial: NCT00671216
Drug: GSK233705
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive 200 (mcg) microgram once daily as a single dose
Trial: NCT00671216
Drug: GW642444
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive 50 mcg once daily as a single dose
Trial: NCT00671216
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching study medication will be inhaled by subjects
Trial: NCT01948895
Drug: Desvenlafaxine
RxNorm normalized name: Desvenlafaxine
DrugBank: Desvenlafaxine (DB06700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be initiated on 50 mg/day of Desvenlafaxine. No dose changes will be allowed for the first four weeks. If there is partial or no response after four weeks, dosage will then be increased to 100mg/day, based on tolerability and the Investigator's judgment.
Trial: NCT03757858
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive standard chemotherapy until disease progression, unacceptable toxicity or patient refusal.
Trial: NCT03535935
Drug: Astragalus Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 grams of water soluble astragalus sachets (equivalent to 15g raw herbs) administrated orally on top of standard medical care for 48 weeks.~Patients will have 5 days of medicine per week and will be advised to take the medicine once daily dissolved in boiling water in the first 5 days of the week.
Trial: NCT02131012
Drug: Intravitreal Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1-4 mg intravitreal celecoxib
Trial: NCT00455156
Drug: 150 mg of Nestorone and 15 mg of ethinyl estradiol (150/15 NES/EE CVR)
RxNorm normalized name: ethinyl estradiol 0.15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg of Nestorone and 15 mg of ethinyl estradiol (150/15 NES/EE CVR), administered via vaginal ring, used on a 21/7 days in/out schedule for no more than one year.
Trial: NCT00708110
Drug: GSK1349572
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1349572 is an experimental drug being developed for the treatment of HIV. It is in the class of integrase inhibitors.
Trial: NCT00708110
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is a tablet with no drug in it.
Trial: NCT00808951
Drug: Artemether-lumefantrine
RxNorm normalized name: artemether-lumefantrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemether-lumefantrine by Novartis was the first fixed-dose ACT that was prequalified by WHO in April 2004. A 3-day, 6-dose regimen of AL is recommended for infants and children weighing 5-35 kg and adults weighing \> 35 kg.
Trial: NCT01356875
Drug: HIDRA/VPA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In each cycle (30 days), Hydralazine 50mg tablets every 12 hours and Valproic 500mg tablets every 8 hours will be administrated orally to HYDRA / VPA group.Each patient will receive 6 cycle.
Trial: NCT02611466
Drug: ASP7962
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants receive ASP7962 100 mg orally twice daily, in the morning and evening with or without food (approximately 12 hours).
Trial: NCT02611466
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants receive naproxen 500 mg orally twice daily, in the morning and evening with or without food (approximately 12 hours).
Trial: NCT02611466
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants receive matching placebo orally twice daily, in the morning and evening with or without food (approximately 12 hours).